Indeed, previous reports have described higher proportions (34.8–43.1%) of HER2-positive tumours amongst patients with BM.21,41,42 In our study, patients were included more recently, and HER2-targeted therapies might have been used more often in the early and metastatic phase of the disease. This evidence concerns the gene ERBB2 and neoplasm.